Payment overview · 2025
General Payments
$1,647.22
94 reported records · 19 companies
Healthcare provider profile · identity verified
William N Carlson, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · STATESVILLE, NC · NPI 1396766721
Verified facts
What the public records show
CMS Open Payments records show William N Carlson, PA-C received $1,647.22 in general payments during 2025 across 94 reported records.
Novartis Pharmaceuticals Corporation accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Levorphanol Tartrate, Nurtec Odt, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Belbuca by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $278.80 | 16.9% | 20 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $254.32 | 15.4% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $250.53 | 15.2% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $163.65 | 9.9% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.37 | 6.9% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $110.97 | 6.7% | 6 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $90.81 | 5.5% | 5 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $79.94 | 4.8% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $61.25 | 3.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $48.54 | 3.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $30.66 | 1.9% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $28.46 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.99 | 1.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.00 | 1.4% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $22.08 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.14 | 1.2% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $16.57 | 1.0% | 1 | 2025 |
| Virtus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.42 | 0.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.72 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,647.22 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $278.80 | 20 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $254.32 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $180.75 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $163.65 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $114.37 | 6 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $110.97 | 6 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $86.20 | 10 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $79.94 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $69.78 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $61.25 | 2 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $48.54 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.66 | 3 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| GELSYN-3 Normalized: gelsyn 3 |
Device | Bioventus LLC | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| LEVORPHANOL TARTRATE Normalized: levorphanol tartrate |
Drug | Virtus Pharmaceuticals LLC | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LEVORPHANOL TARTRATE levorphanol tartrate |
2025 | Levorphanol Tartrate | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 1112 | 175 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 725 | 123 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 593 | 94 |
| Gabapentin | Gabapentin | 442 | 93 |
| Pregabalin | Pregabalin | 434 | 70 |
| Tizanidine Hcl | Tizanidine Hcl | 391 | 78 |
| Morphine Sulfate Er | Morphine Sulfate | 349 | 61 |
| Xtampza Er | Oxycodone Myristate | 217 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 204 | 52 |
| Tramadol Hcl | Tramadol Hcl | 103 | 18 |
| Trazodone Hcl | Trazodone Hcl | 85 | 18 |
| Meloxicam | Meloxicam | 82 | 19 |
| Morphine Sulfate | Morphine Sulfate | 78 | 14 |
| Methocarbamol | Methocarbamol | 74 | 15 |
| Oxycontin | Oxycodone Hcl | 61 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 13 |
| Lidocaine | Lidocaine | 57 | 15 |
| Baclofen | Baclofen | 55 | 15 |
| Fentanyl | Fentanyl | 52 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 52 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Belbuca | Buprenorphine Hcl | 47 | suppressed |
| Ibuprofen | Ibuprofen | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 13 |
| Buprenorphine Hcl | Buprenorphine Hcl | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 27 | suppressed |
| Buprenorphine | Buprenorphine | 26 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 19 | suppressed |
| Ztlido | Lidocaine | 19 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Symproic | Naldemedine Tosylate | 16 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 14 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Levorphanol Tartrate | Levorphanol Tartrate | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,647.22 · 94 records | Novartis Pharmaceuticals Corporation | ACTHAR, Bimzelx, COSENTYX, ENBREL, GELSYN-3, Gazyva, General - Therapies, JOURNAVX, LEVORPHANOL TARTRATE, NURTEC ODT, OFEV, OTEZLA, PURIFIED CORTROPHIN GEL, QULIPTA, SAPHNELO, SIMPONI ARIA, TAVNEOS, TONMYA, TREMFYA, Tymlos, UBRELVY, XTAMPZA, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Levorphanol Tartrate play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error